echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sales volume of 5 pharmaceutical companies in the first half of the year is gratifying. Xiumeile leads the world's top 100 pharmaceutical companies

    Sales volume of 5 pharmaceutical companies in the first half of the year is gratifying. Xiumeile leads the world's top 100 pharmaceutical companies

    • Last Update: 2018-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] more than half of 2018 has passed, and the global drug market has also ushered in a great harvest in the first half of the year The products of major pharmaceutical companies have attracted the attention of pharmaceutical professionals Recently, the Ministry of science and technology released the top 100 list of global drug sales in the first half of 2018 Excluding 8 cooperative products, 92 products together generated sales of 134331 million US dollars (about 919.603 billion yuan) Among them, Roche, BMS, Aberdeen, Johnson & Johnson, Pfizer products sales accounted for the top five Roche products: 7 total sales: 14.671 billion US dollars in the top 100, Roche's products account for 7, among which Herceptin, melowa and avidin are ranked 4, 5 and 7 respectively Herceptin is Roche's drug, with sales of $3.654 billion in the first half of 2018 According to Roche's 2017 financial report, Herceptin sales accounted for 17% of Roche's sales Herceptin's sales volume was CHF 7.014 billion, an increase of 3% compared with 2016 The sales volume of Herceptin was about RMB 46.84 billion (converted according to the middle rate of RMB exchange rate of the State Administration of foreign exchange on December 29, 2017) BMS products: 5 total sales: US $10.877 billion in the first half of 2018, 5 products of BMS have entered the top 100, among which, alental and nawumab have entered the top 10, occupying 2 and 8 places respectively The author understands that in June this year, nambumab of BMS was approved in China for the treatment of locally advanced or metastatic non-small cell carcinoma patients with disease progression or intolerability after previous chemotherapy, and became the PD-1 / PD-L1 inhibitor approved for marketing in China It's worth mentioning that Elliott of BMS is also gradually making efforts, from the previous top five to the top five EBV products: 1 total sales: US $9.894 billion According to the Ministry of science and technology, Sumeria music continues to maintain its leading position Once again, in the first half of 2018, the global drug sales reached the top 100, with sales more than double that of the second place The sales volume in half a year reached 9.894 billion US dollars, which failed to achieve a breakthrough of 10 billion US dollars in half a year The author has learned that since it was approved for listing in the United States in 2002, Sumeria has been approved for 14 indications in the world According to the data of Aberdeen, in 2017, xiumeile's sales volume reached US $18.5 billion, with the global prescription drug sales volume for six consecutive years, known as the "drug king" in the world J & J products: 7 total sales: US $9.808 billion in the first half of the year, 7 products of J & J entered the top 100, but no products entered the top 10 Stellara (ulinuzumab) was the best seller, ranking 14th As a classic standard drug for psoriasis, although it has been repeatedly defeated by new stars such as anti-il17a in clinical practice, stellara still surged 24% in 2017 and exceeded 4 billion US dollars thanks to the overall rapid expansion of the drug market for autoimmune diseases In addition, abitron has become the second largest high sales product of Johnson & Johnson It is reported that the drug was recognized shortly after it was put on the market It can significantly reduce the level of prostate specific antigen in prostate cancer patients, facilitate tumor atrophy, prolong the life span of patients with advanced prostate cancer for several years, and become another heavy bomb drug for Johnson & Johnson Pfizer products: 5 total sales: US $8.619 billion This time, Pfizer has 5 products in the top 100 and three products in the top 20, namely prevanr, pregabalin and ibrance Prevnar vaccine belongs to the innovative health (IH) Department of Pfizer Its main treatment areas include: internal medicine, vaccine, oncology, inflammation and immunology, rare diseases, consumer health care and brands such as prevnar / Prevenar 13 Xeljanz, eliquis, Lyrica (USA, Japan and some other markets), enli Enbrel (outside USA and Canada), Viagra (USA and Canada), ibrance and xtandi, as well as several well-known OTC products.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.